PCRX — Pacira BioSciences, Inc. Stock Price, Chart & AI Report

Neutral May 8, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences announced inducement equity awards to ten new employees on May 4, 2026, including stock options for 36,800 shares and restricted stock units for 27,700 shares. The awards were granted under the company's Amended and Restated 2014 Inducement Plan with an exercise price of $24.69 per share.

PCRX inducement awards stock options restricted stock units employee compensation equity grants non-opioid pain therapies EXPAREL

Sentiment note

The article reports a routine corporate action (employee inducement awards) which is standard business practice. While the company's Q1 2026 results mentioned in the promotional section show revenue growth of 5% and EXPAREL volume growth of 7%, the main article focuses on administrative equity grants without material business impact implications.

Positive May 1, 2026 • 12:17 UTC The Motley Fool • Sarah Sidlow

Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release

Pacira BioSciences CFO Shawn Cross exercised and sold 12,941 shares for approximately $326,000 on April 23, 2026, representing 10.94% of his direct holdings. The transaction was part of a pre-planned Rule 10b5-1 trading plan. Despite the insider sale, the company reported strong Q1 2026 results with $177 million in revenue (5% YoY growth) and beat analyst expectations, with the stock rising about 12% in April.

PCRX insider sale CFO stock transaction Rule 10b5-1 trading plan non-opioid pain management Q1 earnings pharmaceutical company stock options exercise

Sentiment note

The company beat Q1 2026 analyst expectations on both revenue and earnings, reported 5% YoY revenue growth to $177 million, demonstrated volume gains across all three commercial products, and has promising pipeline developments including a completed Phase 3 registrational study for Zilretta. The stock rose 12% in April ahead of earnings release. While the CFO's insider sale could be viewed negatively, it was part of a pre-planned trading arrangement and does not overshadow the strong operational performance.

Positive Apr 13, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures

Pacira BioSciences presented real-world data demonstrating that EXPAREL (bupivacaine liposome injectable suspension) is associated with lower total healthcare costs and reduced opioid utilization in outpatient total hip and knee arthroplasty procedures. Three studies showed cost savings ranging from $7,332 to $13,022 over 6 months post-surgery, with a projected cumulative cost difference of $117,868 per 1 million members by year 3 compared to ropivacaine.

PCRX EXPAREL bupivacaine liposome total hip arthroplasty total knee arthroplasty healthcare costs opioid reduction non-opioid pain management

Sentiment note

The company presented multiple real-world studies demonstrating significant cost savings and clinical benefits of EXPAREL in orthopedic procedures. Data showed lower total healthcare costs ($7,332-$13,022 savings over 6 months), reduced opioid utilization, and positive budget impact analysis. These findings support market expansion and strengthen the company's value proposition to payers and providers.

Neutral Mar 6, 2026 • 13:00 UTC GlobeNewswire Inc. • Na

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences announced inducement equity awards to three new employees on March 3, 2026, including stock options for 2,400 shares and restricted stock units for 5,500 shares. The awards were granted under the company's Amended and Restated 2014 Inducement Plan with an exercise price of $22.10 per share.

PCRX inducement awards stock options restricted stock units employee compensation equity grants non-opioid pain therapies

Sentiment note

The article reports a routine corporate action (employee inducement awards) that is standard business practice. There is no indication of positive or negative business developments, financial performance, or strategic changes. The announcement is purely procedural in nature.

Positive Jan 26, 2026 • 09:51 UTC GlobeNewswire Inc. • Researchandmarkets.Com

Corticosteroids Market Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The global corticosteroids market is projected to grow from USD 6.24 billion in 2025 to USD 8.45 billion by 2031 at a CAGR of 5.18%, driven by rising chronic diseases like asthma and COPD. However, safety concerns from prolonged usage and a shift toward biologics and localized therapies present significant challenges. Innovations in drug delivery systems and extended-release formulations are reshaping the market.

GSK PCRX OCUL ABBV corticosteroids market asthma COPD drug delivery systems

Sentiment note

ZILRETTA extended-release injection generated $118.1 million in net product sales in 2024, reflecting successful commercialization of advanced localized delivery technology for osteoarthritis pain management.

Neutral Oct 27, 2025 • 12:00 UTC GlobeNewswire Inc. • Pacira Biosciences, Inc.

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

Pacira BioSciences received a Paragraph IV Certification Notice from Qilu Pharmaceutical regarding a generic equivalent filing for EXPAREL, challenging 18 of Pacira's patents. Pacira intends to vigorously defend its intellectual property rights.

PCRX EXPAREL patent generic drug intellectual property FDA

Sentiment note

Company is proactively responding to a potential patent challenge by preparing legal action to protect its intellectual property

Positive Oct 23, 2025 • 12:00 UTC GlobeNewswire Inc. • Pacira Biosciences, Inc.

Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®

Pacira BioSciences will present research at AMCP Nexus 2025 highlighting the clinical effectiveness and economic benefits of EXPAREL, a non-opioid pain therapy, with multiple studies focusing on pain management in knee and shoulder surgeries.

PCRX non-opioid pain management EXPAREL surgery healthcare economics

Sentiment note

Company is presenting multiple research studies demonstrating the clinical and economic value of their non-opioid pain management solutions, indicating strong research and innovation capabilities

Positive Oct 3, 2025 • 12:00 UTC GlobeNewswire Inc. • Pacira Biosciences, Inc.

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences granted inducement awards to 15 new employees, including 18,000 stock options and 32,600 restricted stock units, to incentivize new hires under their Inducement Plan.

PCRX stock options inducement awards employee compensation equity grants

Sentiment note

The company is actively hiring and investing in new talent by offering substantial equity compensation, indicating growth and confidence in future prospects

Positive Sep 5, 2025 • 12:00 UTC GlobeNewswire Inc. • Pacira Biosciences, Inc.

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences granted stock options and restricted stock units to nine new employees under its Inducement Plan, with 13,000 stock options and 18,100 restricted stock units awarded.

PCRX stock options inducement awards employee compensation equity non-opioid pain therapies

Sentiment note

The company is expanding its workforce and offering competitive equity compensation, indicating growth and financial stability

Positive Jun 18, 2025 • 12:00 UTC GlobeNewswire Inc. • N/A

Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025

Pacira BioSciences debuted a new film at the BIO 2025 convention, highlighting the journey of a couple who found relief from chronic pain through non-opioid treatments. The film showcases the impact of innovative pain management solutions and the importance of patients having options beyond opioids.

PCRX Pacira BioSciences non-opioid pain therapies chronic pain opioid crisis

Sentiment note

The article highlights Pacira BioSciences' commitment to developing and promoting innovative, non-opioid pain management solutions, which is seen as a positive step in addressing the opioid crisis and improving patient outcomes.

Negative May 27, 2025 • 01:54 UTC GlobeNewswire Inc. • Grabar Law Office

Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)

Grabar Law Office is investigating potential breaches of fiduciary duties by officers and directors of DoubleVerify, NAPCO, Pacira Biosciences, and Treace Medical Concepts.

DV NSSC PCRX TMCI DoubleVerify NAPCO Pacira Biosciences Treace Medical Concepts

Sentiment note

The article indicates that Grabar Law Office is investigating whether Pacira's officers and directors breached their fiduciary duties, as a securities fraud class action complaint alleges the company made false and misleading statements about the validity and scope of its patents.

Negative Mar 14, 2025 • 00:04 UTC GlobeNewswire Inc. • N/A

PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX

Pacira BioSciences, Inc. is facing a securities class action lawsuit due to alleged false and/or misleading statements about the patent protection of its drug Exparel, which led to investor losses.

PCRX Pacira BioSciences securities class action patent protection Exparel

Sentiment note

The article discusses a securities class action lawsuit against Pacira BioSciences, alleging that the company made false and/or misleading statements about the patent protection of its drug Exparel, which led to investor losses.